Abacus Life, Inc. 9.875% Fixed Rate Senior Notes due 2028
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABLLL research report →
Price Chart
About the company
Abacus Life, Inc. operates as an alternative asset management firm, primarily concentrating its investments in active life insurance policies. The company's business model involves acquiring existing life insurance policies and then, via a specific origination procedure, linking these policies to potential purchasers.
- CEO
- Jay Jackson
- IPO
- 2023
- Employees
- 157
- HQ
- Orlando, US
Get TickerSpark's AI analysis on ABLLL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.50B
- P/E
- 16.68
- Fwd P/E
- 25.66
- PEG
- 0.06
- P/S
- 2.14
- P/B
- 1.32
- EV/EBITDA
- 8.45
- Div Yield
- 3.25%
- Gross Margin
- 70.06%
- Op Margin
- 30.81%
- Net Margin
- 12.67%
- ROE
- 8.21%
- ROIC
- 6.23%
Latest fiscal year · YoY change
- Revenue
- $235.24M+110.2%
- Gross Profit
- $169.17M+68.2%
- Op Income
- $87.05M
- Net Income
- $36.53M+252.4%
- EPS
- $0.38+211.8%
- OCF Growth
- +87.7%
- FCF Growth
- +87.3%
- 52W High
- $27.60
- 52W Low
- $20.52
- 50D MA
- $25.39
- 200D MA
- $25.19
- Beta
- -0.47
- RSI (14)
- 83
- Avg Volume
- 5.21K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Abacus posted another strong quarter with revenue and earnings growth, raised full-year guidance, and highlighted accelerating momentum in LifeARC, securitization, and capital conversion.· November 5, 2026
- Q3 revenue was $76.9 million, up 22% year over year, with adjusted EBITDA of $42.3 million and a 55% margin.
- Adjusted net income of $29.4 million beat prior guidance, prompting a second increase to full-year 2026 guidance.
- Longevity fund inflows reached $452.4 million in Q3 and $997 million year-to-date, while cash EBITDA over the last 12 months was $203.2 million, or 132% of adjusted EBITDA.
- The company closed its largest securitization to date, a more than $400 million structure that was 2x oversubscribed and is expected to become a repeatable channel.
- Management said LifeARC is still early but gaining traction, with 357 inquiries to date and over $500 million in investable assets in the pipeline.
Abacus reported Q3 2026 revenue of $76.9 million, up 22% year over year. Life Solutions revenue was $71.3 million, up 32% from $54.1 million a year ago, and Technology Services revenue was $0.6 million, up 155% from $0.2 million. Adjusted EBITDA was $42.3 million with a 55% margin, adjusted net income was $29.4 million, adjusted EPS was $0.29, and adjusted ROE was 26%, up 440 basis points year over year. Operating expenses were $43.4 million. Cash at quarter-end was $104 million, policy assets were $370 million, and long-term debt excluding nonrecourse liabilities was $366 million. The company raised full-year 2026 adjusted net income guidance to $104.5 million to $106.5 million from $100 million to $106 million, and adjusted EPS to $1.05 to $1.07 from $1.00 to $1.05. For Q4, management guided to adjusted net income of $28 million to $30 million and adjusted EPS of $0.28 to $0.30.
Jay Jackson framed the quarter as a milestone period, emphasizing operational outperformance and strategic progress across LifeARC, the ABX fund, and securitization. He said the company is becoming a platform that connects longevity data to both institutional capital markets and individual financial planning, and repeatedly highlighted external validation through oversubscribed capital raises and investor demand. His tone was confident and upbeat, with a strong focus on long-term optionality, especially around LifeARC and the wealth transfer opportunity.
William McCauley emphasized that results came in ahead of plan, with Q3 adjusted net income of $29.4 million above the high end of prior guidance. He raised full-year 2026 guidance for adjusted net income and EPS, cited Q3 capital deployment of $235.3 million and year-to-date deployment of $596.8 million, and noted longevity fund inflows of about $452.4 million in the quarter. He also highlighted cash conversion strength, saying year-to-date operating cash flow was $1.46 for every dollar of adjusted EBITDA, and pointed to a solid balance sheet with $104 million in cash and $366 million of long-term debt excluding nonrecourse liabilities. He also noted the $100 million share repurchase authorization, $1.7 million of buybacks in the quarter at an average of $8.13, and a 10% increase in the regular annual dividend to $0.22 per share.
Analysts asked about the potential impact of a political shift in Washington, and management said a lower estate-tax threshold could actually increase demand for insurance policies, while overall regulation should remain manageable regardless of party. Questions on the ABX fund focused on distribution timing, and Jay Jackson said platform rollout is progressing, with meaningful flows expected in Q1 and interest from RIAs, pension funds, and large financial institutions. Analysts also pressed on the decline in AUM-fee revenue and the role of securitization; management called the fee dip a one-time effect tied to maturing closed-end and offshore funds and said securitization should lift fee-related revenue over time. On capital allocation, management said buybacks are weighed against ROE and stock ROI, while debt decisions will be made opportunistically and remain conservative.
The call showed multiple sources of momentum: revenue and earnings beat guidance, cash conversion remained strong, and management raised full-year targets again. Abacus also demonstrated that its distribution model is expanding, with record securitization execution, growing longevity-fund inflows, and early traction in LifeARC and new partnerships like Retirable and Manning & Napier.
A key risk is that several of the company’s newer growth drivers are still early, especially LifeARC and the ABX fund, so near-term monetization is not yet fully proven. Management also acknowledged quarter-to-quarter noise in AUM fees from maturing funds and said capital deployment cannot keep rising at the recent pace indefinitely, suggesting growth will need to normalize. The company’s economics also remain sensitive to capital markets conditions, securitization execution, and interest-rate trends, which management noted can affect realized gains and funding decisions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 38.6%
- Shares Outstanding
- 97.75M
- Float Shares
- 37.73M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 10 ETFs
Biggest fund positions in ABLLL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | McNealy Sean | other | 28,027 |
| Oct 30, 26 | Kirby Kevin Scott | other | 28,027 |
| Oct 30, 26 | Ganovsky Matthew | other | 28,027 |
| Oct 27, 26 | Gusky Adam Samuel | other | 13,400 |
| Sep 23, 26 | Ganovsky Matthew | sell | 22,800 |
| Sep 23, 26 | Kirby Kevin Scott | sell | 22,745 |
| Sep 23, 26 | McNealy Sean | sell | 22,700 |
| Sep 18, 26 | McNealy Sean | sell | 24,000 |
| Sep 21, 26 | McNealy Sean | sell | 35,854 |
| Sep 22, 26 | McNealy Sean | sell | 21,100 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABLLL coverage
Recent articles, reports, and earnings notes.
No research on ABLLL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABLLL report →